4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Pacira BioSciences, Inc. (PCRX) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Brisbane, United States with about 825 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, PCRX reported $726M in revenue and $7M in net income.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Interactive charts & full statements → Open the PCRX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $726M | $701M | $675M | $667M |
| Gross Profit | $577M | $530M | $490M | $468M |
| Operating Income (EBIT) | $19M | $90M | $88M | $60M |
| Net Income | $7M | ($100M) | $42M | $16M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $177M | $197M | $180M | $181M | $169M | — |
| Gross Profit | $141M | $157M | $145M | $140M | $135M | — |
| Operating Income (EBIT) | $5M | ($11M) | $13M | $9M | $8M | — |
| Net Income | $3M | $2M | $5M | ($5M) | $5M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $1.3B | $1.6B | $1.6B | $1.7B | — |
| Total Liabilities | $572M | $775M | $704M | $906M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PCRX viewer.
About TickerBase · Data methodology & sources